[Treatment of borreliosis].
Segura Porta
F
F
Programa Asistencial de Enfermedades Infecciosas, Corporació Sanitària Parc Taulí, Sabadell, Barcelona.
Fernández
M M
MM
D000208:Acute Disease; D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D001096:Arachnid Vectors / Q000382:microbiology; D001170:Arthritis, Infectious / Q000188:drug therapy / Q000382:microbiology; D001898:Borrelia / Q000276:immunology / Q000302:isolation & purification; D001899:Borrelia Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D009202:Cardiomyopathies / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D002648:Child; D002908:Chronic Disease; D000013:Congenital Abnormalities / Q000209:etiology; D016207:Cytokines / Q000502:physiology; D004269:DNA, Bacterial / Q000097:blood; D018450:Disease Progression; D004197:Disease Reservoirs; D005260:Female; D005315:Fetal Diseases / Q000382:microbiology; D006801:Humans; D008193:Lyme Disease / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D008297:Male; D009422:Nervous System Diseases / Q000188:drug therapy / Q000382:microbiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D013030:Spain / Q000453:epidemiology; D013987:Ticks / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D016207:Cytokines; D004269:DNA, Bacterial